The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.

Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM

Archives of internal medicine1 Jun 2006Cited by 62 (Europe PMC)

PMID16772249DOI10.1001/archinte.166.11.1209PepBankPUB-16772249

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoOther
In a microsimulation of osteoporotic women, sequential teriparatide/alendronate cost 156,500 dollars per QALY compared with alendronate.
In plain wordsIn a computer model, sequential teriparatide/alendronate cost 156,500 dollars per quality-adjusted life-year compared with alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSequential regimen cost per QALY
Study
n: not reported in source
Microsimulation of postmenopausal white women with low bone density and prevalent vertebral fracture
Comparator
Alendronate
Outcome group
Cost-effectiveness · Whole body
Measurements
Incremental cost per QALY
156,500 dollars/QALY
sequential teriparatide/alendronate versus alendronate
Source sentences
Summary
The cost of sequential teriparatide/alendronate therapy was 156,500 dollars per QALY compared with alendronate.
3 context sentences(design, population, supporting numbers)
Summary · context
We developed a microsimulation with a societal perspective.
Summary · context
We evaluated postmenopausal white women with low bone density and prevalent vertebral fracture.
Summary · context
The interventions were usual care (UC) (calcium or vitamin D supplementation) compared with 3 strategies: 5 years of alendronate therapy, 2 years of teriparatide therapy, and 2 years of teriparatide therapy followed by 5 years of alendronate therapy (sequential teriparatide/alendronate).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1677224901
02Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoOther
In a microsimulation of osteoporotic women, teriparatide alone was more expensive than alendronate.
In plain wordsIn a computer model, teriparatide alone cost more than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTeriparatide monotherapy cost
Study
n: not reported in source
Microsimulation of postmenopausal white women with low bone density and prevalent vertebral fracture
Comparator
Alendronate
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Teriparatide treatment alone was more expensive and produced a smaller increase in QALYs than alendronate.
3 context sentences(design, population, supporting numbers)
Summary · context
We developed a microsimulation with a societal perspective.
Summary · context
We evaluated postmenopausal white women with low bone density and prevalent vertebral fracture.
Summary · context
The interventions were usual care (UC) (calcium or vitamin D supplementation) compared with 3 strategies: 5 years of alendronate therapy, 2 years of teriparatide therapy, and 2 years of teriparatide therapy followed by 5 years of alendronate therapy (sequential teriparatide/alendronate).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1677224902
03Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoOther
In a microsimulation of osteoporotic women, teriparatide alone produced a smaller QALY gain than alendronate.
In plain wordsIn a computer model, teriparatide alone added fewer quality-adjusted life-years than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTeriparatide monotherapy QALY gain
Study
n: not reported in source
Microsimulation of postmenopausal white women with low bone density and prevalent vertebral fracture
Comparator
Alendronate
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Teriparatide treatment alone was more expensive and produced a smaller increase in QALYs than alendronate.
3 context sentences(design, population, supporting numbers)
Summary · context
We developed a microsimulation with a societal perspective.
Summary · context
We evaluated postmenopausal white women with low bone density and prevalent vertebral fracture.
Summary · context
The interventions were usual care (UC) (calcium or vitamin D supplementation) compared with 3 strategies: 5 years of alendronate therapy, 2 years of teriparatide therapy, and 2 years of teriparatide therapy followed by 5 years of alendronate therapy (sequential teriparatide/alendronate).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1677224903
04Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoOther
In a microsimulation, teriparatide remained less cost-effective than alendronate even with efficacy lasting 15 years after treatment cessation.
In plain wordsIn a computer model, teriparatide remained less cost-effective than alendronate even with benefits lasting 15 years after treatment stopped.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseMonotherapy cost-effectiveness sensitivity analysis
Study
n: not reported in source
Microsimulation of postmenopausal white women with low bone density and prevalent vertebral fracture
Comparator
Alendronate
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
For sensitivity analysis, teriparatide alone was less cost-effective than alendronate even if its efficacy lasted 15 years after treatment cessation.
3 context sentences(design, population, supporting numbers)
Summary · context
We developed a microsimulation with a societal perspective.
Summary · context
We evaluated postmenopausal white women with low bone density and prevalent vertebral fracture.
Summary · context
The interventions were usual care (UC) (calcium or vitamin D supplementation) compared with 3 strategies: 5 years of alendronate therapy, 2 years of teriparatide therapy, and 2 years of teriparatide therapy followed by 5 years of alendronate therapy (sequential teriparatide/alendronate).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1677224904
05Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoOther
In a microsimulation, sequential teriparatide/alendronate remained less cost-effective than alendronate even if the alendronate phase eliminated fractures.
In plain wordsIn a computer model, sequential teriparatide/alendronate remained less cost-effective than alendronate even if fractures disappeared during the alendronate phase.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSequential regimen cost-effectiveness sensitivity analysis
Study
n: not reported in source
Microsimulation of postmenopausal white women with low bone density and prevalent vertebral fracture
Comparator
Alendronate
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Sequential teriparatide/alendronate therapy was less cost-effective than alendronate even if fractures were eliminated during the alendronate phase,
3 context sentences(design, population, supporting numbers)
Summary · context
We developed a microsimulation with a societal perspective.
Summary · context
We evaluated postmenopausal white women with low bone density and prevalent vertebral fracture.
Summary · context
The interventions were usual care (UC) (calcium or vitamin D supplementation) compared with 3 strategies: 5 years of alendronate therapy, 2 years of teriparatide therapy, and 2 years of teriparatide therapy followed by 5 years of alendronate therapy (sequential teriparatide/alendronate).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1677224905
06Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoOther
The simulation estimated sequential treatment below 50,000 dollars per QALY with a 60% price decrease, elderly women with T scores ≤-4.0, or equally effective 6-month treatment.
In plain wordsThe computer model estimated sequential treatment below 50,000 dollars per quality-adjusted life-year under specified price, elderly high-risk population, or equally effective shorter-treatment assumptions.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSequential regimen cost-effectiveness under favorable assumptions
Study
n: not reported in source
Microsimulation of postmenopausal white women with low bone density and prevalent vertebral fracture
Comparator
Alendronate
Outcome group
Cost-effectiveness · Whole body
Measurements
Cost-effectiveness threshold
< 50,000 dollars/QALY
under any stated favorable assumption
Teriparatide price reduction
60%
price sensitivity assumption
Source sentences
Summary
although its cost-effectiveness was less than 50,000 dollars per QALY if the price of teriparatide decreased 60%, if used in elderly women with T scores of -4.0 or less, or if 6 months of teriparatide therapy had comparable efficacy to 2 years of treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
We developed a microsimulation with a societal perspective.
Summary · context
We evaluated postmenopausal white women with low bone density and prevalent vertebral fracture.
Summary · context
The interventions were usual care (UC) (calcium or vitamin D supplementation) compared with 3 strategies: 5 years of alendronate therapy, 2 years of teriparatide therapy, and 2 years of teriparatide therapy followed by 5 years of alendronate therapy (sequential teriparatide/alendronate).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1677224906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.